

Supplementary Table 1. Characteristics of kidney transplant recipients by incident post-kidney transplantation all-cause dementia

Variable	No dementia (n = 8,786)	Dementia (n = 55)	p-value
Age (yr)	52.4 ± 7.4	60.5 ± 6.1	<0.001
40–44	1,469 (16.7)	0 (0)	
45–49	1,846 (21.0)	3 (5.5)	
50–54	2,177 (24.8)	7 (12.7)	
55–59	1,680 (19.1)	14 (25.5)	
60–64	1,076 (12.2)	14 (25.5)	
65–69	429 (4.9)	14 (25.5)	
≥70	109 (1.2)	3 (5.5)	
Male sex	5,325 (60.6)	25 (45.5)	0.75
Year grading (yr)			0.004
2007–2009	1,940 (22.1)	18 (32.7)	
2010–2012	2,996 (34.1)	25 (45.5)	
2013–2015	3,850 (43.8)	12 (21.8)	
Income			0.30
Medical aid	1,254 (14.3)	5 (9.1)	
Q1	1,271 (14.5)	6 (10.9)	
Q2	1,279 (14.6)	11 (20.0)	
Q3	1,810 (20.6)	8 (14.5)	
Q4	3,172 (36.1)	25 (45.5)	
Charlson comorbidity index			0.003
0	63 (0.7)	1 (1.8)	
1–2	2,618 (29.8)	6 (10.9)	
3–4	2,552 (29.0)	14 (25.5)	
≥5	3,553 (40.4)	34 (61.8)	
Diabetes mellitus	3,749 (42.7)	38 (69.1)	<0.001
Hypertension	8,169 (93.0)	54 (98.2)	0.21
Dyslipidemia	4,927 (56.1)	39 (70.9)	0.04
Cardiovascular disease	2,128 (24.2)	21 (38.2)	0.03
Dialysis modality			0.14
Preemptive	2,825 (32.2)	16 (29.1)	
Hemodialysis	3,856 (43.9)	22 (40.0)	
Peritoneal dialysis	1,597 (18.2)	16 (29.1)	
Mixed	508 (5.8)	1 (1.8)	
Dialysis vintage period	3.0 ± 3.4	2.5 ± 2.7	0.16
<3 mo	3,199 (36.4)	16 (29.1)	
3 mo–1 yr	752 (8.6)	6 (10.9)	
1–2 yr	661 (7.5)	8 (14.5)	
2–3 yr	566 (6.4)	8 (14.5)	
3–4 yr	567 (6.5)	3 (5.5)	
4–5 yr	554 (6.3)	3 (5.5)	
>5 yr	2,487 (28.3)	11 (20.0)	
Immunosuppressive treatment			
Desensitization	1,461 (16.6)	11 (20.0)	0.63
Induction			0.25
No use	370 (4.2)	0 (0)	
ATG	820 (9.3)	4 (7.3)	
Basiliximab	7,596 (86.5)	51 (92.7)	
Maintenance CNI			0.39
No use	242 (2.8)	0 (0)	
Tacrolimus	7,221 (82.2)	45 (81.8)	
Cyclosporine	1,323 (15.1)	10 (18.2)	

Data are expressed as mean ± standard deviation or number (%).
 ATG, antithymocyte globulin; NI, calcineurin inhibitor; Q, quartile.